Axium Healthcare Pharmacy Dispensing New Breakthrough Breast Cancer Drug IBRANCE®

Share Article

IBRANCE's® Breakthrough Therapy Designation from the FDA has brought hope to thousands in the breast cancer community.

Axium Healthcare Pharmacy announced today that it is dispensing Pfizer’s long awaited breast cancer drug IBRANCE® (palbociclib).

The approval, which came nearly two months ahead of schedule through the FDA’s Breakthrough Therapy Designation and Priority Review Program, has brought hope to thousands in the breast cancer community. The American Cancer Society estimates that in 2015 there will be 234,190 new breast cancer cases and approximately 40,000 deaths.

IBRANCE® is a prescription medicine that is used along with the medicine letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as the first hormone-based therapy for their metastatic disease.

IBRANCE® is an endocrine-based therapy that is delivered in capsule form. In combination with letrozole, IBRANCE® has been shown to almost double the time between tumor progression, delaying the need for later-line therapies including other hormonal agents and chemotherapies.

Axium is an authorized Limited Distribution Pharmacy for IBRANCE®. Full prescribing information for IBRANCE® is available at

--About Axium Healthcare Pharmacy--

Founded in 2000, Axium Healthcare Pharmacy, Inc. is a nationwide provider of specialty pharmacy services. A wholly-owned subsidiary of The Kroger Company, Axium provides drug therapies and patient support services to treat chronic, genetic, and other complex conditions such as Hepatitis C, Multiple Sclerosis, Cancer, Rheumatoid Arthritis, and a number of others.

For more information, contact Axium Healthcare Pharmacy at 888.315.3395 or visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Wendy Bacigalupi

Roxie Mooney
Follow >
Axium Healthcare Pharmacy
since: 01/2011
Like >
Follow us on
Visit website